Loading page…
PREPAIR-VAC will connect viral forecasting with vaccine design, manufacturing and preclinical testing. Faster outbreak response is the goal, not a demonstrated result.
Listen to this story
PREPAIR-VAC is a four-year Horizon Europe effort to link viral-evolution forecasting with vaccine design, manufacturing and preclinical validation, using H1N1 as its starting point. NEC OncoImmunity is responsible for antigen prediction and vaccine design, but the approximately €6.5 million budget is for the consortium: the EU project record allocates the subsidiary €1,262,587.50. Lower Saxony researchers plan to assemble an influenza database covering hundreds of thousands of viruses for AI training. The project runs from September 1, 2026, through August 31, 2030, and remains a proof-of-concept program—not evidence of vaccine protection or faster deployment.
NEC announced the project on October 26; consortium partners held the official launch and kick-off meeting on October 22.
NEVEZYNE will contribute silkworm-based protein production, while Université Jean Monnet–Saint-Étienne will validate vaccine candidates in preclinical models.
About €650,000 is earmarked for Hannover partners’ work on ethical, legal and societal questions and public-health recommendations.
A European research consortium is setting out to design vaccines for emerging threats by anticipating how viruses evolve. NEC announced on October 26, 2026, that its OncoImmunity subsidiary will handle AI-powered prediction and vaccine design for PREPAIR-VAC, a four-year, EU-funded project with an approximately €6.5 million budget.
The European Vaccine Initiative coordinates the Horizon Europe-funded collaboration. Its October 26 launch announcement identifies October 22 as the official launch and kick-off meeting, when consortium partners gathered to agree on their scientific, technical and operational roadmap. The research period began on September 1, 2026, and runs through August 31, 2030.
The headline budget covers the consortium, not NEC alone. The European Commission's project record lists a net EU contribution of €1,262,587.50 for NEC OncoImmunity. NEC describes the subsidiary as the project's primary initiator, with responsibility for antigen prediction and vaccine design.
The project targets a timing problem. The Commission's description says current vaccine-design approaches are reactive: researchers need to know the circulating strain before designing a vaccine. That leaves a window in which a virus can spread while development and production catch up. PREPAIR-VAC aims to move prediction earlier in that process.
Influenza, specifically H1N1, is the model disease. The consortium intends to anticipate viral evolution before outbreaks, identify antigenic regions shared across strains and design vaccine candidates around those targets. NEC says its approach is intended to address current pathogen diversity while anticipating future mutations, with broadly protective vaccines as the goal.
Training data is one concrete contribution. The Lower Saxony State Health Authority, or NLGA, says its researchers will build an influenza sequence database containing genetic information from hundreds of thousands of viruses. That database will underpin AI training, connecting the consortium's public-health and genomics expertise with its vaccine-design work.
The consortium brings together complementary expertise across the vaccine development lifecycle to generate a solid proof-of-concept package using preclinical and translational models.
Dr. Kaidre Bendjama, Chief Scientific Officer, NEC OncoImmunity
PREPAIR-VAC's intended output is a modular development pipeline, rather than an AI design tool in isolation. Its objectives connect pathogen forecasting, target selection and vaccine design with manufacturability. The consortium also plans to combine AI-tool development and validation with manufacturing and formulation technologies that could support rapid increases in production.
Those validation goals put the announcement in perspective: this is a research programme working toward proof of concept, not a disclosure of demonstrated vaccine protection or measured time savings. The intended reach extends beyond its influenza starting point. EVI says the platform is being designed for adaptation to future emerging infectious diseases.
The consortium is also treating acceptance and deployment as research questions. EVI plans stakeholder engagement to identify barriers facing AI-enabled vaccines and foster discussion among researchers, policymakers, healthcare professionals and the public. Its stated concerns include trustworthiness, transparency and bias, alongside the ethical, societal and regulatory dimensions of development.
Uppsala University, NLGA and Hannover Medical School contribute expertise in ethical, legal and societal frameworks. In Hannover, NLGA researchers will work with Professor Sabine Salloch, director of the medical school's Institute for Ethics, History and Philosophy of Medicine, to examine questions surrounding AI-supported vaccine technologies. That work runs alongside the scientific development programme.
The Hannover partners' intended output is practical: recommendations for public-health services and health policy, translating the research into guidance for institutions that would face future outbreaks. NLGA says roughly €650,000 of the project's funding will go to the Hannover partners. Their remit therefore reaches beyond supplying genetic data for the AI models.
Loading discussion...
Join the conversation
Explain when public input would be most useful.
Be the first to share a perspective or an experience.
Reader comments
Newest comments first. Replies stay oldest first.